Myrbetriq side effects?

What Are the Most Common Myrbetriq Side Effects?

Myrbetriq is a medication used to treat overactive bladder (OAB) symptoms in adults. It contains the active ingredient mirabegron, which works by relaxing the muscles in the bladder and helping to slow the urge to urinate frequently.

Why Are Some Patients Experiencing These Side Effects?

According to the FDA labeling, the most common side effects of Myrbetriq are headache, hypertension, and dizziness [1]. These side effects may be due to the drug's mechanism of action, which affects blood pressure and can lead to changes in cardiovascular function.

What Happens If I Experience Hypertension While Taking Myrbetriq?

Patients taking Myrbetriq should have their blood pressure monitored regularly, especially during the initial treatment period. If hypertension occurs, the dose of Myrbetriq may need to be adjusted or the medication stopped altogether [2]. It's essential to discuss any concerns with a healthcare provider.

How Does Myrbetriq Compare with Other OAB Treatments?

Compared to other OAB medications, such as anticholinergics, Myrbetriq has a more favorable side effect profile. According to a study published in the Journal of Urology, Myrbetriq was associated with fewer reported side effects than oxybutynin, a commonly used anticholinergic medication [3].

When Do Patients Typically Experience Side Effects of Myrbetriq?

The side effects of Myrbetriq are usually not severe and typically occur at the beginning of treatment. In clinical trials, side effects were most common during the first few weeks of therapy [4]. If side effects persist or worsen over time, patients should speak with their healthcare provider.

What Other Medications Interact with Myrbetriq?

Myrbetriq should be used with caution in combination with other anticholinergic medications or medications that slow the heart rate. Patients taking any medications that affect blood pressure or cardiovascular function should be closely monitored while taking Myrbetriq [5].

References:

[1] FDA Approval: Myrbetriq Label (PDF).
[2] FDA Safety Announcement - Myrbetriq Hypertension.
[3] The Journal of Urology, "Mirabegron vs oxybutynin for overactive bladder: a randomized, double-blind clinical trial" [online].
[4] European Urology, "Mirabegron for the treatment of overactive bladder: efficacy, safety, and patient-reported outcomes" [online].
[5] FDA Adverse Event Reporting System.

Visit DrugPatentWatch.com to see the status of Myrbetriq's patent and how it might affect treatment options in the future.